<DOC>
	<DOCNO>NCT02554448</DOCNO>
	<brief_summary>The purpose study evaluate value dynamic change detect CTCs peripheral blood stage III rectal cancer patient undergo neoadjuvant Folfox treatment chemoradiotherapy , surgery .</brief_summary>
	<brief_title>Detection CTCs Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy</brief_title>
	<detailed_description>Circulating tumor cell ( CTCs ) potential provide surrogate for'real-time biopsy ' tumor biological activity . Enumeration CTCs rectal cancer patient could play important role diagnosis , predict risk tumor recurrence effectiveness neoadjuvant therapy . The investigator choose several timepoints detect dynamic change CTCs,1 day 1st ,3rd 5th ( patient need surgery ) neoadjuvant therapy course,1 day 7days ,3 month,6 month surgery . Approximately 7.5-mL ethylene diamine tetraacetic acid ( EDTA ) -blood draw vein puncture patient rectal cancer . Briefly , number CTCs count cellsearch system , record analysed investigator .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>1 . Age : &gt; 18 year old . 2 . Diagnosis stage III rectal cancer base histology . 3 . Will receive neoadjuvant treatment use Folfox chemoradiotherapy . 4 . Life expectancy : Greater 3 month . 5 . Patients severe inflammation , vasculitis . 6 . Ability understand study protocol willingness sign write informed consent document 1 . Patients primary tumor except rectal cancer . 2 . History coagulation disorder anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Circulating Tumor Cells</keyword>
	<keyword>rectal Neoplasms</keyword>
	<keyword>neoadjuvant otherapy</keyword>
</DOC>